Company profile: Geneseeq
1.1 - Company Overview
Company description
- Provider of NGS-based genomic testing and research services for cancer care, offering pan-cancer and tumor-specific panels plus project design, sequencing and data analysis. Products include GeneseeqPrimeβ’ (437-gene solid tumor panel with mutation, tumor mutational burden and DNA mismatch repair insights), GeneseeqPrimeβ’ HRD for PARP inhibitor guidance, Hemasalusβ’ DNA/Hemarnaβ’ RNA for hematological cancers, and Shieldingβ’ ULTRA MRD ctDNA detection.
Products and services
- GeneseeqPrimeβ’: Solid-tumor-focused kit analyzing 437 genes, reporting mutations, tumor mutational burden, and DNA mismatch repair genes to inform therapeutic decisions
- Genomic Testing: NGS-based service featuring a pan-cancer panel analyzing over 400 genes and disease-specific panels to match patients with optimal treatments
- Research Services: End-to-end program with over 2000 projects in collaboration with biopharma and research partners, covering project design, sequencing, and data analysis
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Geneseeq
Delfi Diagnostics
HQ: United States
Website
- Description: Provider of high-precision, non-invasive blood tests for early cancer detection, including the FirstLook Lung test using DNA fragment patterns; leverages machine learning and fragmentomics to analyze cell-free DNA fragments; and runs the CASCADE-LUNG clinical study to validate blood-based lung cancer screening technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Delfi Diagnostics company profile β
Cepheid
HQ: United States
Website
- Description: Provider of accurate, easy-to-use molecular diagnostic systems and tests that automate complex procedures for institutions of any size. Offerings include the GeneXpert System and single-use Xpert cartridges for nucleic acid extraction, amplification, and detection, plus Xpert Xpress PCR tests for Strep A, SARS-CoV-2, CoV-2/Flu/RSV, and Flu A/B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Cepheid company profile β
Korro Bio
HQ: United States
Website
- Description: Provider of efficient, selective RNA editing solutions leveraging natural processes: OPERA, a platform using oligonucleotides for precise single-base edits to modulate protein function; KRRO-110, an oligonucleotide candidate for Alpha-1 Antitrypsin Deficiency via SERPINA1 RNA editing; and CHORDs, customized high-fidelity oligonucleotides for RNA deamination.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Korro Bio company profile β
Rome Therapeutics
HQ: United States
Website
- Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Rome Therapeutics company profile β
Lysogene
HQ: France
Website
- Description: Provider of basic research and clinical development of gene therapy for neurodegenerative disorders, developing AAV vectors, with a mission to improve the health of patients with incurable, life-threatening conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Lysogene company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Geneseeq
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Geneseeq
2.2 - Growth funds investing in similar companies to Geneseeq
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Geneseeq
4.2 - Public trading comparable groups for Geneseeq
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β